Related Experiment Video
Updated: Sep 21, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
New trends in the treatment of diabetic nephropathy in children
Alberto Verrotti1, Daniela Trotta, Giovanna di Corcia
1Department of Pediatrics, Ospedale Policlinico, Via dei Vestini, Chieti, Italy. chiarelli@unich.it
Insights
Diabetic nephropathy in children with Type 1 diabetes is concerning. Microalbuminuria during puberty may resolve, but hypertension worsens outcomes, necessitating careful reno-protective drug use discussions.
Area of Science:
- Nephrology
- Diabetology
- Pediatrics
Background:
- Diabetic nephropathy is a leading cause of morbidity and mortality in Type 1 diabetes patients.
- Persistent microalbuminuria is a key risk marker in adults, while puberty presents a critical period for microvascular complications in children.
- Hypertension exacerbates both micro and macrovascular complications.
Purpose of the Study:
- To review controversial aspects of managing microalbuminuria in pediatric Type 1 diabetes.
- To discuss the natural history of microalbuminuria during puberty and its implications for treatment.
- To evaluate the role of reno-protective drugs in pediatric diabetic nephropathy.
Main Methods:
- Review of existing literature on diabetic nephropathy in pediatric populations.
- Analysis of the significance of microalbuminuria and hypertension during puberty.
- Discussion of current and potential therapeutic strategies, including ACE inhibitors and ARBs.
Main Results:
- Microalbuminuria in pediatric Type 1 diabetes during puberty may be transient, with up to 50% reverting to normoalbuminuria.
- Hypertension is a significant risk factor accelerating complications.
- Angiotensin-converting enzyme inhibitors are currently favored for treating diabetic nephropathy, with angiotensin II receptor antagonists as a potential future choice.
Conclusions:
- There is a lack of consensus regarding the treatment and timing of reno-protective interventions in pediatric patients with microalbuminuria.
- Further research is needed to clarify the natural history of microalbuminuria in this age group to guide therapeutic decisions.
- Optimizing management strategies is crucial to prevent long-term renal damage in children with Type 1 diabetes.
Abstract:
Nephropathy is the main cause of morbidity and mortality in patients with Type 1 diabetes and persistent microalbuminuria is the best marker of the consequent risk for its development in adults. In the paediatric population, puberty has long been recognised as a major risk period for the development of microangiopathic complications, although it is not necessarily associated with the progression to frank proteinuria. In fact, as many as 50% of subjects might revert to normoalbuminuria. Hypertension is a further risk factor and accelerates the progression of micro and macrovascular complications. There is evidence that angiotensin-converting enzyme inhibitors reduce renal damage by one or more mechanisms independent of their antihypertensive effects and they are the drug class of choice for the treatment of diabetic nephropathy. However, as angiotensin II receptor antagonists are more specific they might become the obvious treatment choice in the near future. There is no consensus on who should be treated with reno-protective drugs in the paediatric population, and when this should occur, due to the lack of a clear definition of the natural history of microalbuminuria in this age group. In this review controversial aspects of this issue are presented and discussed.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Kidney Transplant III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Diabetic Retinopathy
Diabetic Nephropathy